SEC Form 4 · accession 0001735276-18-000039

ALNYLAM PHARMACEUTICALS, INC. · ALNY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jul 25, 2018

Accepted (ET)

Jul 27, 2018 · 4:07 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001178670

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jul 25, 2018	M	50,000	$21.35	A	201,297	D
Common Stock^F2	Jul 25, 2018	S	2,000	$102.51	D	199,297	D
Common Stock^F3	Jul 25, 2018	S	3,847	$103.69	D	195,450	D
Common Stock^F4	Jul 25, 2018	S	7,758	$104.83	D	187,692	D
Common Stock^F5	Jul 25, 2018	S	34,995	$105.83	D	152,697	D
Common Stock^F6	Jul 25, 2018	S	1,400	$106.25	D	151,297	D
Common Stock^F7	Apr 16, 2018	J	30	$0.00	A	2,990	I	by Managed Account
Common Stock^F7	Jul 10, 2018	J	31	$0.00	A	3,021	I	by Managed Account

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F8	$21.35	Jul 25, 2018	M	50,000	D	—	Dec 8, 2018	Common Stock	50,000	98,636	D

F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 16, 2018. The 50,000 options exercised and sold by the reporting person were due to expire on December 8, 2018.
F2Sale prices ranged from $101.99 to $102.94.
F3Sale prices ranged from $103.10 to $104.04.
F4Sale prices ranged from $104.17 to $105.15.
F5Sale prices ranged from $105.17 to $106.13.
F6Sale prices ranged from $106.18 to $106.33.
F7Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F8The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.